These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11597452)

  • 41. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection.
    Crotty S; Hix L; Sigal LJ; Andino R
    J Gen Virol; 2002 Jul; 83(Pt 7):1707-1720. PubMed ID: 12075090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Excretion of wild-type and vaccine-derived poliovirus in the feces of poliovirus receptor-transgenic mice.
    Boot HJ; Kasteel DT; Buisman AM; Kimman TG
    J Virol; 2003 Jun; 77(11):6541-5. PubMed ID: 12743311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrograde axonal transport of poliovirus and EV71 in motor neurons.
    Ohka S; Hao Tan S; Kaneda S; Fujii T; Schiavo G
    Biochem Biophys Res Commun; 2022 Oct; 626():72-78. PubMed ID: 35973377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Transgenic Mouse Model of Poliomyelitis.
    Koike S; Nagata N
    Methods Mol Biol; 2016; 1387():129-44. PubMed ID: 26983733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor.
    Mahon BP; Katrak K; Nomoto A; Macadam AJ; Minor PD; Mills KH
    J Exp Med; 1995 Apr; 181(4):1285-92. PubMed ID: 7699320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mouse neuropathogenic poliovirus strains cause damage in the central nervous system distinct from poliomyelitis.
    Gromeier M; Lu HH; Wimmer E
    Microb Pathog; 1995 Apr; 18(4):253-67. PubMed ID: 7476091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transgenic mice susceptible to poliovirus.
    Koike S; Taya C; Kurata T; Abe S; Ise I; Yonekawa H; Nomoto A
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):951-5. PubMed ID: 1846972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The promoters for human and monkey poliovirus receptors. Requirements for basic and cell type-specific activity.
    Solecki D; Schwarz S; Wimmer E; Lipp M; Bernhardt G
    J Biol Chem; 1997 Feb; 272(9):5579-86. PubMed ID: 9038165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Reevaluate the effect of G-480 point mutation that determines the neurovirulence of type I vaccine polioviruses].
    Zhang Y; Yan DM; Wang DY; Zhao R; Zhang DY; Ye XF; Zhu SL; An HQ; Xu WB
    Bing Du Xue Bao; 2007 Jan; 23(1):1-8. PubMed ID: 17886713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice.
    Levenbook I; Nomura T
    Lab Anim Sci; 1997 Apr; 47(2):118-20. PubMed ID: 9150487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poliovirus neurovirulence.
    Racaniello VR
    Adv Virus Res; 1988; 34():217-46. PubMed ID: 2843017
    [No Abstract]   [Full Text] [Related]  

  • 52. Selective isolation of poliovirus in recombinant murine cell line expressing the human poliovirus receptor gene.
    Hovi T; Stenvik M
    J Clin Microbiol; 1994 May; 32(5):1366-8. PubMed ID: 8051271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Poliovirus spreads from muscle to the central nervous system by neural pathways.
    Ren R; Racaniello VR
    J Infect Dis; 1992 Oct; 166(4):747-52. PubMed ID: 1326581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus.
    Ida-Hosonuma M; Iwasaki T; Yoshikawa T; Nagata N; Sato Y; Sata T; Yoneyama M; Fujita T; Taya C; Yonekawa H; Koike S
    J Virol; 2005 Apr; 79(7):4460-9. PubMed ID: 15767446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Random selection: a model for poliovirus infection of the central nervous system.
    Georgescu MM; Balanant J; Ozden S; Crainic R
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1819-28. PubMed ID: 9266975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template.
    Cello J; Paul AV; Wimmer E
    Science; 2002 Aug; 297(5583):1016-8. PubMed ID: 12114528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Poliovirus infection in the transgenic mouse model].
    Koike S
    Jikken Dobutsu; 1993 Jul; 42(3):296-9. PubMed ID: 8394822
    [No Abstract]   [Full Text] [Related]  

  • 58. Determinants of poliovirus neurovirulence.
    Gromeier M; Mueller S; Solecki D; Bossert B; Bernhardt G; Wimmer E
    J Neurovirol; 1997 May; 3 Suppl 1():S35-8. PubMed ID: 9179789
    [No Abstract]   [Full Text] [Related]  

  • 59. An ex vivo murine model to study poliovirus-induced apoptosis in nerve cells.
    Couderc T; Guivel-Benhassine F; Calaora V; Gosselin AS; Blondel B
    J Gen Virol; 2002 Aug; 83(Pt 8):1925-1930. PubMed ID: 12124456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.
    Taffs RE; Chernokhvostova YV; Dragunsky EM; Nomura T; Hioki K; Beuvery EC; Fitzgerald EA; Levenbook IS; Asher DM
    J Infect Dis; 1997 Feb; 175(2):441-4. PubMed ID: 9203668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.